Wegovy for postpartum weight loss: what the science actually shows

What did @ashleymolina24 actually say?

Almost nothing, medically speaking. The video's transcript is a single sentence: "And with that, the 2023 season comes to an end. Goodnight." The substantive claims live entirely in the caption, where she credits Wegovy and her doctor with helping her feel less depressed and more comfortable in her body after two pregnancies. That's the claim we're actually fact-checking here, not anything she said on camera.

She describes feeling "depressed and unhappy in my own skin" after giving birth and frames Wegovy as part of a transformation that helped her "refind" herself. She's careful enough to mention her doctor, which matters. But the caption blurs the line between postpartum depression as a clinical condition and postpartum body dissatisfaction, and that distinction is not a small one.

Does the science back this up?

Semaglutide (the active ingredient in Wegovy) does produce real, clinically significant weight loss. That part is not in dispute. Whether weight loss reliably resolves postpartum depression is a much messier question, and the research does not support a clean causal story.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4mg semaglutide lost an average of 14.9% of body weight versus 2.4% with placebo. That's a meaningful result. However, STEP 1 excluded postpartum individuals and people with active mood disorders. So the trial population is not who @ashleymolina24 represents.

Postpartum depression affects roughly 10-15% of birthing parents (O'Hara and McCabe, 2013, Annual Review of Clinical Psychology). The standard of care is psychotherapy, particularly cognitive behavioral therapy, and antidepressants where appropriate. There is no published clinical evidence that GLP-1 receptor agonists treat postpartum depression directly. Some emerging data (Mansur et al., 2023, Translational Psychiatry) suggests GLP-1 pathways may influence mood, but that research is preliminary and not specific to postpartum populations.

What did they get wrong (or right)?

She got one thing right that a lot of these videos skip: she mentioned her doctor. That matters because Wegovy is a prescription medication and framing it as something you take with medical supervision is accurate and responsible.

What's misleading is the implicit equation of weight loss with depression treatment. If she experienced genuine postpartum depression, Wegovy was almost certainly not the primary intervention. If what she experienced was more accurately body image distress or postpartum weight-related anxiety, that's a real and valid experience, but calling it depression conflates two things that have different treatments and different clinical trajectories.

There's also a real concern about postpartum use of semaglutide. Wegovy is not recommended during breastfeeding (FDA prescribing information, 2023). The caption gives no timeline information, so we don't know whether her sons were infants or toddlers when she started. That context would change the risk picture significantly. Presenting a before-and-after without that context is not dishonest exactly, but it is incomplete in a way that could mislead new mothers watching this.

What should you actually know?

If you're postpartum and struggling, a few things are worth knowing before this video shapes your expectations. First, weight loss medications are not first-line treatment for postpartum depression. If you're clinically depressed, you need a proper evaluation, not a GLP-1. Second, Wegovy is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition. It is not approved to treat mood disorders of any kind.

Third, postpartum weight retention is common and does affect body image and mental health (Bogaerts et al., 2013, Midwifery). Wanting to address it is legitimate. But the path from "I felt depressed after two kids" to "Wegovy changed my life" skips over the clinical complexity of what postpartum depression actually is and how it actually gets treated.

Finally, individual results on semaglutide vary considerably. The STEP trials show averages. Some people lose significantly more, some significantly less, and discontinuation rates in real-world settings are higher than in controlled trials (Wilding et al., 2022, Diabetes, Obesity and Metabolism). A single person's transformation video is not a clinical prediction for what will happen to you.